Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ALK-3/BMPR1A Protein, 1mg  

Recombinant human ALK-3/BMPR1A Protein, 1mg

Recombinant Human ALK-3 /BMPR1A Protein (rhALK3), Gln24-Arg152 was expressed in human 293 cells (HEK293).

Synonym: recombinant, human, protein BMPR-1A, ALK-3, BMPR1A, ALK3, CD292, bone morphogenetic protein receptor type IA

More details

AL3-H5228-1K

Availability: within 7 days

1 200,00 €

Background
The bone morphogenetic protein receptor, type IA also known as BMPR1A or ALK3 is a protein which in humans is encoded by the BMPR1A gene. BMPR1A has also been designated as CD292 (cluster of differentiation 290). The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A (this protein) and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2.[1] Alk3-mediated BMP signaling in AV endocardial/mesenchymal cells plays a central role during cushion morphogenesis.[2]

Source
Recombinant Human ALK-3 /BMPR1A Protein (rhALK3), Gln24-Arg152 (Accession # CAA80257) was expressed in human 293 cells (HEK293)

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 15.7 kDa. The protein migrates as 23-34 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
N/A 

References

(1) Mishina Y, Starbuck MW , et al.(2004). J. Biol. Chem. 279 (26): 27560–6
(2) Song L, Fässler R, et al. (2007). Dev Biol. 301(1):276-86